|
"yen c j"的相關文件
顯示項目 401-410 / 471 (共48頁)
<< < 36 37 38 39 40 41 42 43 44 45 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2016-06 |
Exposure-Response relationship of second-line ramucirumab in East Asian patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
|
Kim, T. Y.;Yen, C. -J.;Al-Batran, S. -E.;Gao, L.;Ferry, D.;Hsu, Y.;Cheng, R.;Orlando, M.;Ohtsu, A. |
| 臺大學術典藏 |
2016 |
Interplay between Superoxide Dismutase, Glutathione Peroxidase, and Peroxisome Proliferator Activated Receptor Gamma Polymorphisms on the Risk of End-Stage Renal Disease among Han Chinese Patients
|
Chao C.-T.; Chen Y.-C.; Chiang C.-K.; Huang J.-W.; CHENG-CHUNG FANG; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2016 |
Interplay between Superoxide Dismutase, Glutathione Peroxidase, and Peroxisome Proliferator Activated Receptor Gamma Polymorphisms on the Risk of End-Stage Renal Disease among Han Chinese Patients
|
Chao C.-T.; Chen Y.-C.; Chiang C.-K.; JENQ-WEN HUANG; Fang C.-C.; Chang C.-C.; Yen C.-J. |
| 國立成功大學 |
2015-12-01 |
Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
|
Yen, C. J.; Klochikhin, A.; Cohen, E.; Vermorken, J.; Harrington, K.; Tahara, M.; Ge, Y.; Geib, J.; Jin, F.; Burtness, B. |
| 國立成功大學 |
2015-12-01 |
A clinical survey on satisfaction of pain management in hospitalized patients with cancer in Taiwan
|
Lin, J.; Chang, C. -S.; Lee, M. -Y.; Liao, Y. -M.; Wu, M. -F.; Sung, Y. -C.; Rau, K. -M.; Yu, M. -S.; Lai, P. -Y.; Chiou, T. -J.; Chen, J. -S.; Lee, K. -D.; Hwang, W. -L.; Liu, T. -C.; Yen, C. -J.; Shao, Y. -Y.; Hsieh, R. -K. |
| 國立成功大學 |
2015-12-01 |
Impact and predictive factor of undertreatment of analgesic drug in outpatients with cancer: a nationwide of clinical pain survey in Taiwan
|
Yang, C. -K.; Chou, W. -C.; Shen, W. -C.; Chen, J. -S.; Lee, K. -D.; Yen, C. -J.; Lai, P. -Y.; Shao, Y. -Y.; Hwang, W. -L.; Chiou, T. -J.; Sung, Y. -C.; Rau, K. -M.; Liao, Y. -M.; Chang, C. S.; Wu, M. -F.; Lee, M. -Y.; Yu, M. -S.; Liu, T. -C.; Hsieh, R. -K. |
| 國立成功大學 |
2015-09 |
Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
|
Chau, I.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Kudo, M.; Pfiffer, T. F.; Hatano, E.; Chung, H. C.; Kubackova, K.; Phelip, J. M.; Brandi, G.; Ohkawa, S.; Li, C. P.; Okusaka, T.; Yang, L.; Abada, P.; Zhu, A. |
| 國立成功大學 |
2015-06-01 |
Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
|
Palmer, D.; Meyer, T.; Chao, Y.; Deptala, A.; Fartoux, L.; Feng, Y. -H.; Graham, J.; Lin, D. -Y.; Ma, Y. T.; Peck-Radosavljevic, M.; Ross, P.; Ryoo, B. -Y.; Yen, C. -J.; Hocke, J.; Vlassak, S.; Wenz, A.; Loembe, A. -B.; Cheng, A. -L. |
| 國立成功大學 |
2015-05-01 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, J. S.; Hsu, C.; Chiang, N. J.; Tsai, C. S.; Tsou, H. H.; Huang, S. F.; Bai, L. Y.; Chang, I. C.; Shiah, H. S.; Ho, C. L.; Yen, C. J.; Lee, K. D.; Chiu, C. F.; Rau, K. M.; Yu, M. S.; Yang, Y.; Hsieh, R. K.; Chang, J. Y.; Shan, Y. S.; Chao, Y.; Chen, L. T. |
| 國立成功大學 |
2015-03 |
Genetic polymorphisms in the prostaglandin pathway genes and risk of head and neck cancer
|
Lee, W-T; Huang, C-C; Chen, K-C; Wong, T-Y; Ou, C-Y; Tsai, S-T; Yen, C-J; Fang, S-Y; Lo, H-I; Wu, Y-H; Hsueh, W-T; Yang, M-W; Lin, F-C; Hsiao, J-R; Huang, J-S; Chang, J-Y; Chang, K-Y; Wu, S-Y; Lin, C-L; Wang, Y-H; Weng, Y-L; Yang, H-C; Chang, J. S. |
顯示項目 401-410 / 471 (共48頁)
<< < 36 37 38 39 40 41 42 43 44 45 > >>
每頁顯示[10|25|50]項目
|
